Cost-effectiveness of First-Line Enfortumab Vedotin in Addition to Pembrolizumab for Metastatic Urothelial Carcinoma in the United States
Frontiers in Immunology（2024）
关键词
enfortumab vedotin,pembrolizumab,bladder cancer,cost-effectiveness,the United States
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要